Sacramento, CA -- August 07, 2018 -- InvestorsHub NewsWire --
Spotlight Growth has published new content on Innovest Global, Inc.
(OTC PINK: IVST). Innovest Global, Inc. is a diversified holding
company that focuses on acquiring niche, high-growth businesses
that are capable of generating significant annual revenue. The
company’s planned subsidiaries operate across telehealth, biotech,
commercial energy, business-to-business distribution, national call
center and auto sales.
The report provides an overview of Innovest Global, Inc., its
subsidiaries, financials, biotech industry analysis, U.S./global
cancer rates and more.
American Cancer Society: Estimated 21.7 Million New
Cancer Cases By 2030
Cancer continues to be a major global healthcare issue, as
millions of people die each year from the illness. Most of us are
familiar with the pain and suffering that cancer can cause, which
shows that there is a desperate need for a modern treatment plan.
For too long the primary treatment for cancer has continued to be
chemotherapy, which itself can be extremely painful and cause other
complications.
According to the U.S. Centers for Disease
Control (CDC), cancer is the second leading cause of death
within the United States, behind heart disease. In the latest data
available, the CDC notes that 595,930 Americans died from cancer in
2015.
Unfortunately, many health and science experts do not see an end
in sight for cancer. According to the American Cancer
Society (ACS), there will be an estimated 1.74 million new
cases of cancer that are diagnosed in the United States alone this
year.
The global trends are far more pessimistic. In 2012,
the ACS reported that there were 14.1 million new cases
in cancer resulting in 8.2 million deaths globally. By 2030, the
ACS estimates that there will be around 21.7 million new cases of
cancer resulting in 13 million deaths worldwide. However, the group
does admit that “the future burden will probably be even larger
because of the adoption of western lifestyles, such as smoking,
poor diet, physical inactivity, and few childbirths, in
economically developing countries,” according to the
report.
According to Grand View Research, the global biotechnology
market is forecast to reach $727.1 billion USD by 2025, which
represents an annual growth rate of 7.40%.
IVST: Completion of 20% Stake In StemVax, Brain Cancer
Vaccine Technology Awarded U.S. Patent
Innovest Global has continued to impress through the halfway
point of 2018. The Cleveland, Ohio-based conglomerate has
managed to close and integrate five acquisitions into its two
operational divisions: Biotechnology & Health Sciences and
Commercial & Industrial. The management team continues to fire
on all cylinders, as Innovest Global reported three straight months
of record profits through June 2018.
The latest completed acquisition by Innovest Global was the 20%
stake in StemVax Therapeutics, a translational biotechnology
company. StemVax is currently in the process of developing a cancer
vaccine therapy to treat again brain tumors, specifically
Glioblastomas (the same form of brain cancer as Arizona
Senator John McCain).
StemVax Therapeutics’ flagship technology, the StemVax Glioblast
(SVX-GB), is described as “a cancer vaccine, which is a medication
that stimulates or restores the immune system’s ability to fight an
existing cancer by strengthening the body’s natural defenses
against the cancer cells. It is a meaningful technology, which
could significantly improve the quality of life and prognosis for
the many people who suffer from brain tumors,” according to the
company’s release.
Shortly after Innovest Global announced
the completion of stake acquisition in StemVax
Therapeutics, the biotechnology company announced that its cancer
vaccine technology has been awarded a U.S. Patent. Specifically,
the patent relates to “cancer antigens” and the “treatment of
cancer using vaccination therapy.”
“Patent approval is the trigger for us to engage major
health organizations, to continue the progress toward the ‘StemVax
Glioblast’ brain tumor vaccine going to market and improving
people’s lives. After decades of research, it took nine years in
the patent process, and is a transformational achievement,” said
Dr. Dwain Morris-Irvin, President of Innovest’s Biotech Division.
The patent application was initially filed back in 2008 by a
hospital research organization, and was co-authored by Dr.
Morris-Irvin, who is also the StemVax Chief Science Officer,
according to an Innovest Global corporate release.
On August 6, 2018, Innovest Global made a major announcement
that it has signed an agreement with the
highly-respected Cedars-Sinai Medical Center in Los
Angeles, CA. In the agreement, Innovest has been awarded an
exclusive worldwide license “for all of the intellectual property
needed to commercialize the StemVax Glioblast brain tumor vaccine,”
according to the press release. Cedars-Sinai Medical Center is a
non-profit hospital that is widely considered to be one of the top
hospitals and research organizations in the entire world.
IVST: First Half Accomplishments
Outside of the successful acquisitions, Innovest Global reported
second quarter sales growth of 55.80% compared to the first quarter
2018 ($1.1 million in Q2 versus $708,804 in Q1). Furthermore,
Innovest Global reported current assets of $877,861 and cash
holdings of $561,062. Management notes that there continues to be
no convertible debt, warrants or options outstanding, as of end of
second quarter 2018.
During the first quarter, Innovest Global received its first
institutional shareholder in Winslow Asset Management. The
Ohio-based asset manager purchased 10,000 shares during the first
three months of 2018, according to a 13F filing. After an updated
filing for the second quarter, it is confirmed that Winslow Asset
Management continues to be long shares of Innovest
Global. Winslow stayed put during the second quarter, not adding or
selling their current position.
While there were certainly some enticing entry points that
Winslow Asset Management could have used to engage in dollar-cost
averaging during the second quarter, it is certainly a vote of
confidence that the fund is remaining a bullish stance on
Innovest.
Here is a complete list from a recent Innovest Global press
release, which thoroughly highlighting the
impressive achievements through the first half of
2018:
- Sales are up 55.8%. ($1,104,367 in Q2 compared to $708,804
in Q1). June Sales were highest ever, at 16.8% higher than May, the
previous record.
- End Q2 current assets of $877,861 include cash on hand of
$561,062.
- Our capital structure includes an unchanged free-trading
float of 11,796,710 common shares. There are no convertible debts,
no warrants or options outstanding.
- Our headcount is 44 employees, up from 26 at the start of
the quarter.
- Our stock price is up 725% as of this past Friday, since
our January 2, 2018 close. Since Thursday of last week IVST saw
more than double average trading volume, following the StemVax
announcement.
- We received notice that Winslow Asset Management registered
as a shareholder, marking our first institutional shareholder
position.
- We closed several key contracts with organizations ranging
from local governments, to the United States Navy, University
Hospitals, Cleveland Indians, University of Louisiana, Iowa
Department of Transportation, Houston Metro, Tarkette and a $650K
exclusive contact from Byram Healthcare, a division of a Fortune
500 Company.
- We’ve got a world-class team including two independent
members of our Board of Directors, and our key corporate leadership
is highlighted on our new corporate website.
For more information on Innovest Global, Inc., please
visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/08/06/this-undervalued-gem-has-a-patented-technology-for-treating-cancer-with-vaccination-therapy/
SpotlightGrowth.com is a digital hub for micro-caps,
small-caps, crowdfunding, cryptocurrency, and other emerging growth
investors. SpotlightGrowth.com serves as our media
subsidiary and provides insights on small cap companies.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third
party, to provide investor relations services for its
clients. Spotlight Growth creates exposure for companies
through a customized marketing strategy, including design of
promotional material, the drafting and editing of press releases
and media placement.
All information on featured companies is provided by the
companies profiled, or is available from public sources. Spotlight
Growth and its employees are not a Registered Investment Advisor,
Broker Dealer or a member of any association for other research
providers in any jurisdiction whatsoever and we are not qualified
to give financial advice. The information contained herein is based
on external sources that Spotlight Growth believes to be reliable,
but its accuracy is not guaranteed. Spotlight Growth may
create reports and content that has been compensated by a company
or third-parties, or for purposes of self-marketing. Spotlight
Growth was compensated two thousand five hundred dollars cash and
fifty thousand restricted shares for the creation and dissemination
of this content.
This material does not represent an investment solicitation.
Certain statements contained herein constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may include, without
limitation, statements with respect to the Company’s plans and
objectives, projections, expectations and intentions. These
forward-looking statements are based on current expectations,
estimates and projections about the Company’s industry,
management’s beliefs and certain assumptions made by
management.
The above communication, the attachments and external Internet
links provided are intended for informational purposes only and are
not to be interpreted by the recipient as a solicitation to
participate in securities offerings. Investments referenced
may not be suitable for all investors and may not be permissible in
certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and
employees may have bought or sold or may buy or sell shares in the
companies discussed herein, which may be acquired prior, during or
after the publication of these marketing materials. Spotlight
Growth, its affiliates, officers, directors, and employees may sell
the stock of said companies at any time and may profit in the event
those shares rise in value. For more information on our
disclosures, please
visit: http://spotlightgrowth.com/index.php/disclosures/
Matt Rego 916-525-7147 mrego@spotlightgrowth.com
Innovest Global (CE) (USOTC:IVST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innovest Global (CE) (USOTC:IVST)
Historical Stock Chart
From Sep 2023 to Sep 2024